Wegovy for PCOS and insulin resistance: what TikTok gets right and wrong

What did @ssabrinagori actually say?

Here's the honest problem with this fact-check: the transcript we have from this video is not coherent medical content. The words captured, "Oh my life is changing every day Every bus in the way Oh my dreams is never quite as a team," read like song lyrics or audio bleed, not health claims. So we're working with the hashtags and caption, which do tell us something real.

The caption frames this as a personal journey with Wegovy, referencing insulin resistance and polycystic ovary syndrome (PCOS). The hashtags, #resistenciaainsulina, #sindromedeovariopoliquistico, #procesowegovy, and #saludhormonal, situate this squarely in the GLP-1 for PCOS conversation that's exploding on Spanish-language TikTok. That context matters, even when the verbal content is unclear.

Because we cannot directly quote medical claims from the transcript, this fact-check focuses on what the video's framing implies and whether Wegovy is actually appropriate for people with PCOS and insulin resistance.

Does the science back this up?

Semaglutide's potential in PCOS is genuinely interesting, but the evidence is still thin. The short answer: promising signals, not proven treatment.

A 2023 randomized controlled trial by Cena et al. published in the Journal of Clinical Endocrinology and Metabolism found that GLP-1 receptor agonists improved menstrual regularity and reduced androgen levels in women with PCOS and obesity, but the sample sizes were small and the follow-up periods short. A 2022 meta-analysis by Zheng et al. in Frontiers in Endocrinology found GLP-1 agonists outperformed placebo on weight, fasting insulin, and testosterone in PCOS populations, but the authors flagged significant heterogeneity across studies.

Wegovy specifically, meaning semaglutide 2.4 mg weekly, is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition. Insulin resistance qualifies. PCOS itself does not appear on the FDA label. That distinction matters legally and clinically.

• GLP-1 agonists reduce fasting insulin and HOMA-IR in PCOS patients (Zheng et al., 2022)
• Menstrual cycle improvements have been observed, but are likely secondary to weight loss
• No large-scale RCT has tested semaglutide 2.4 mg specifically in PCOS as a primary endpoint

What did they get wrong (or right)?

Without clear verbal claims, we can't pin a factual error on this creator specifically. But the framing deserves scrutiny.

Presenting Wegovy as part of a PCOS journey, with a "finish line" metaphor, implies the drug is a straightforward solution for a condition it is not approved to treat. That framing can mislead viewers who have PCOS without obesity, or who assume semaglutide addresses the underlying hormonal dysfunction rather than supporting weight loss that secondarily improves symptoms.

What the creator gets right, at least implicitly: Wegovy can be a legitimate tool for people who have both obesity and PCOS. Weight loss of 5 to 10 percent body weight is well-established to improve ovulatory function and insulin sensitivity in PCOS (Lim et al., 2019, Human Reproduction Update). If this creator is using Wegovy under medical supervision with documented insulin resistance or a BMI that meets criteria, that's a defensible clinical path.

What's missing: any acknowledgment that Wegovy is not a PCOS cure, that it requires ongoing use to maintain effects, and that discontinuation typically reverses weight loss within a year (Wilding et al., 2022, Diabetes, Obesity and Metabolism).

What should you actually know?

If you have PCOS and are considering semaglutide, here's what the evidence actually supports, and where it stops.

GLP-1 receptor agonists are not approved specifically for PCOS. They are approved for weight management when certain BMI or weight-related comorbidity criteria are met. Insulin resistance associated with PCOS may qualify as a comorbidity, but that determination belongs with a licensed clinician reviewing your specific labs and history, not a TikTok comment section.

The mechanism is real: semaglutide improves insulin sensitivity, reduces appetite, and supports weight loss. In PCOS, where hyperinsulinemia drives androgen excess, reducing insulin load can improve symptoms. But the drug does not directly fix ovarian function or hormonal signaling. The improvement is downstream of weight change.

• Do not self-diagnose insulin resistance from social media content
• Wegovy requires a prescription and ongoing medical monitoring
• Compounded semaglutide products are not equivalent to FDA-approved Wegovy
• Effects reverse when the medication is stopped in most patients

The "finish line" framing in this video is the part that concerns me most. Chronic conditions like PCOS and insulin resistance do not have finish lines. Medications like Wegovy are tools, not endpoints. Anyone who treats this as a destination rather than ongoing management is setting themselves up for disappointment.